ADARx Pharmaceuticals Appoints Ajim Tamboli, CFA as Chief Financial Officer
2024年7月30日 - 10:05PM
ADARx Pharmaceuticals, Inc. (ADARx), a clinical stage biotechnology
company developing next generation RNA therapeutics, today
announced the appointment of Ajim Tamboli as Chief Financial
Officer (CFO). Mr. Tamboli brings two and a half decades of
lifesciences investing, banking and financial operations plus
strategic leadership experience to ADARx. ADARx has a pipeline of
RNA targeting therapeutics, which are currently focused on treating
diseases in three key areas: genetic disorders, cardiometabolic
conditions and central nervous system.
Mr. Tamboli will be responsible for leading financial operations
while supporting strategic initiatives and business operations. He
will also lead efforts in Business Development, Investor Relations,
and Facilities. Mr. Tamboli also has extensive experience in
initial public and secondary offerings along with a deep network of
peers in investing and banking.
“Ajim has 25 years of broad and relevant industry experience,
including a strong track record in capital raising and in building
and leading financial organizations, and I am pleased to welcome
him to ADARx,” said Zhen Li, PhD, Co-Founder, President and CEO of
ADARx. "Ajim’s experience in biotech financial strategy and
operations, healthcare investing and as a sell-side analyst give
him a unique background and perspective that will make him an
invaluable addition to our leadership team as we continue to focus
on creating value and bringing life-changing RNA medicines to
patients.”
“I am delighted to join ADARx at such an exciting time in the
company’s trajectory. With three clinical-stage programs and
numerous others progressing through research and preclinical
development, I believe that ADARx has great potential to set a new
standard of care for patients,” said Tamboli. “I look forward to
working with the team to support its strategic and financial
objectives as we continue to advance the company’s pipeline of
next-generation RNA medicines across multiple therapeutic
areas.”
Prior to ADARx, Mr. Tamboli was the CFO at Arbor Biotechnologies
and preceding that CFO at Monte Rosa Therapeutics, where he was
responsible for leading private and public fund raises of over
$465M, including an upsized $255M IPO. He previously served as the
CFO of Rodin Therapeutics, where he ran investor fundraising and
supported their successful acquisition by Alkermes. Mr. Tamboli has
extensive experience in healthcare asset management, having managed
a global portfolio of biotech and pharmaceutical companies, notably
as a founding partner of Endurant Capital Management and with
Columbia Management. Earlier in his career, Mr. Tamboli was a
Senior Biotechnology Equity Research Analyst with Lehman
Brothers.
Mr. Tamboli earned an MS in Biotechnology and BS in Biomedical
Science/Entrepreneurial Management from the University of
Pennsylvania School of Engineering and Applied Science/Wharton
School, where he was a Benjamin Franklin Scholar. He is a
CFA® charterholder.
About ADARx Pharmaceuticals ADARx
Pharmaceuticals, Inc. is a clinical stage biotechnology company
committed to turning cutting-edge science into life-saving
therapeutics. ADARx has developed proprietary RNA delivery
platforms and technology for silencing or editing target mRNA.
ADARx has a growing pipeline of RNA therapeutics for treating
diseases across a range of therapeutic areas including genetic,
cardiovascular, complement-mediated and central nervous system
diseases. Follow ADARx on LinkedIn.
ADARx Contacts
Investors
Roselle Corbaley
(877) 232-7974
ir@adarx.com
Media
Michael Beyer
mike@redhousecomms.com